Robert Miller, the patient advocating for Hemispherx Biopharma Inc.’s Ampligen (rintatolimod) for chronic fatigue syndrome by going on a hunger strike in protest of the FDA’s complete response letter, ended the hunger strike over the weekend. Progress was made, he said,…
About a week ago, my obituary arrived by email. But something related, which you might think is weirder, happened Tuesday afternoon, and all of it involves chronic fatigue syndrome (CFS), and Hemispherx Biopharma Inc.’s drug candidate for it, Ampligen.
I was on the phone last week with Rick Andrews, president and CEO of Thrasos, about acute kidney injury (AKI), and how it’s no longer called “acute renal failure,” the latter phrase having been scrapped in recent years.
Join the Conversation